$BMRN

The FDA Calendar to April 2027: 5 Biotech Stocks From the KXCO Biotech Ontology

The KXCO Biotech Ontology's board carries 12 pending FDA filings, due between 10 October 2026 and 23 April 2027. Ranked on approval standing, the top five are BridgeBio's BBP-418, Cogent's bezuclastinib, Belite Bio's tinlarebant, Novo Nordisk's CagriSema and BioMarin's vosoritide. Ranked on consensus upside, they are Cullinan, Savara, Intellia, Mineralys and Pharvaris. No name is on both lists. This report covers BridgeBio, Cogent, Mineralys, Pharvaris and Savara.